As European markets show mixed returns, with the STOXX Europe 600 Index edging higher on hopes of interest rate cuts, investors are keenly analyzing opportunities in value stocks trading below their estimated worth. In this environment, identifying undervalued stocks involves assessing companies that demonstrate strong fundamentals and potential for growth despite broader economic uncertainties.
| Name | Current Price | Fair Value (Est) | Discount (Est) |
| Stellantis (BIT:STLAM) | €10.17 | €20.10 | 49.4% |
| Sanoma Oyj (HLSE:SANOMA) | €9.19 | €18.32 | 49.8% |
| PVA TePla (XTRA:TPE) | €22.52 | €44.13 | 49% |
| Mo-BRUK (WSE:MBR) | PLN308.50 | PLN601.98 | 48.8% |
| Gentili Mosconi (BIT:GM) | €3.30 | €6.54 | 49.5% |
| Figeac Aero Société Anonyme (ENXTPA:FGA) | €10.90 | €21.62 | 49.6% |
| Exel Composites Oyj (HLSE:EXL1V) | €0.393 | €0.78 | 49.4% |
| Digital Workforce Services Oyj (HLSE:DWF) | €2.57 | €5.09 | 49.5% |
| Allcore (BIT:CORE) | €1.355 | €2.66 | 49% |
| Aker BioMarine (OB:AKBM) | NOK90.00 | NOK177.13 | 49.2% |
Here's a peek at a few of the choices from the screener.
Overview: Revenio Group Oyj specializes in ophthalmological devices and software for diagnosing glaucoma, macular degeneration, and diabetic retinopathy across Finland, the United States, and globally, with a market cap of €587.93 million.
Operations: The company's revenue primarily comes from its Health Tech segment, which generated €109.32 million.
Estimated Discount To Fair Value: 28.4%
Revenio Group Oyj is trading at €22.1, significantly below its estimated fair value of €30.88, highlighting potential undervaluation based on cash flows. Recent earnings reports show steady growth with third-quarter sales rising to €25.9 million from €23.9 million year-on-year and net income increasing slightly to €4.6 million. The adoption of a Product Operating Model aims to enhance agility and customer focus, potentially supporting future growth as revenues are expected to outpace the Finnish market at 10.1% annually.
Overview: Absolent Air Care Group AB (publ) specializes in designing, developing, selling, installing, and maintaining air filtration units with a market capitalization of approximately SEK2.42 billion.
Operations: The company's revenue is primarily derived from its Industrial segment, generating SEK1029.08 million, and the Commercial Kitchen segment, contributing SEK243.58 million.
Estimated Discount To Fair Value: 43%
Absolent Air Care Group, trading at SEK214, is significantly undervalued with a fair value estimate of SEK375.41. Despite recent third-quarter sales declining to SEK301.35 million from last year's SEK331.02 million, net income saw a slight increase to SEK19.98 million from SEK19.74 million year-on-year. However, insider selling has been significant recently, which may be a concern for investors considering its strong earnings growth forecast of 42% annually compared to the Swedish market's 13.5%.
Overview: SKAN Group AG, with a market cap of CHF1.11 billion, offers isolators, cleanroom devices, and decontamination processes for the pharmaceutical and chemical industries across Europe, the Americas, Asia, and internationally.
Operations: The company's revenue is primarily derived from its Equipment & Solutions segment, which generates CHF241.46 million, and its Services & Consumables segment, contributing CHF90.67 million.
Estimated Discount To Fair Value: 19.3%
SKAN Group, trading at CHF49.45, is undervalued with a fair value estimate of CHF61.31. Although recent guidance indicates lower 2025 sales and profit due to project delays, the company maintains strong medium-term growth targets supported by a robust project pipeline. Forecasted revenue growth of 15.8% annually outpaces the Swiss market, while earnings are expected to grow significantly at 31.6% per year despite current profit margin declines from last year's levels.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com